VSEE HEALTH INC C/WTS (TO PUR COM)｜10-Q：2025 財年 Q1 營收 3.32 百萬美元

Revenue: As of FY2025 Q1, the actual value is USD 3.321 M.

EPS: As of FY2025 Q1, the actual value is USD -0.24.

EBIT: As of FY2025 Q1, the actual value is USD -1.101 M.

Segment Revenue

• Technology Segment: Total revenue for the three months ended March 31, 2025, was $2,123,871, with subscription fees contributing $827,345, professional services and other fees $896,680, and technical engineering fees $399,846.
• Telehealth Segment: Total revenue for the three months ended March 31, 2025, was $1,197,614, with patient fees contributing $711,264, telehealth fees $483,850, and institutional fees $2,500.

Operational Metrics

• Gross Margin: Technology segment gross margin was $1,049,747, and Telehealth segment gross margin was $810,224 for the three months ended March 31, 2025.
• Operating Loss: Technology segment operating loss was - $354,237, and Telehealth segment operating loss was - $583,174 for the three months ended March 31, 2025.

Cash Flow

• Net Cash Used in Operating Activities: For the three months ended March 31, 2025, net cash used in operating activities was - $440,493.
• Net Cash Used in Investing Activities: For the three months ended March 31, 2025, net cash used in investing activities was - $11,873.
• Net Cash Provided by Financing Activities: For the three months ended March 31, 2025, net cash provided by financing activities was $536,373.

Unique Metrics

• Interest Expense: Total interest expense for the three months ended March 31, 2025, was $730,665.

Future Outlook and Strategy

• Core Business Focus: The company plans to leverage its industry relationships with government, hospital systems, and insurance providers to increase its customer base and expand within the telehealth market.
• Non-Core Business: The company is exploring additional financing options to support its working capital needs and fund growth initiatives.

Priority

• The company emphasizes strategies with concrete projections, such as expanding its customer base and leveraging industry relationships, over generic statements.